Pancreastatin: Multiple Actions on Human Intermediary Metabolism<i>in Vivo</i>, Variation in Disease, and Naturally Occurring Functional Genetic Polymorphism
Daniel T. O’Connor(Nova Southeastern University), Víctor Sánchez‐Margalet(Hospital Universitario Virgen Macarena), Joshua W. Smith(VA San Diego Healthcare System), Laurent Taupenot(University of California San Diego), Clayton Smiley(VA San Diego Healthcare System), Manjula Mahata(Uppsala University), Carmen González-Yanes(Hospital Universitario Virgen Macarena), Robert R. Henry(United States Department of Veterans Affairs), Sushil K. Mahata(Unknown), Stephen Funk(VA San Diego Healthcare System), Rany M. Salem(Human Longevity (United States)), Gen Wen(Uppsala University), Kimberly L. Harper(University of California San Diego), Fangwen Rao(Uppsala University), Peter E. Cadman(Norwegian Womens Public Health Association)
Cited by 87
Related Papers
Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects
|New England Journal of Medicine|2006|1.3k
Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY
|Endocrine Practice|2016|875
The Chromogranin–Secretogranin Family
|New England Journal of Medicine|2003|820
Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
|Patient Preference and Adherence|2016|758